Utilization Investigation of EGFR-TKI in the Patients with Lung Cancer in 11 Hospitals of Zhejiang Province during 2009 and 2015
- VernacularTitle:2009~2015年浙江省11家医院肺癌患者表皮生长因子受体酪氨酸激酶抑制药使用调查
- Author:
Luo FANG
;
Wenxiu XIN
;
Lingya CHEN
;
Yinghui TONG
;
Xiaowei ZHENG
;
Haiying DING
;
Ping HUANG
- Keywords:
Epidermal growth factor receptor tyrosine kinase inhibitor;
Patients with lung cancer;
Consumption sum;
DDDs;
DDC;
DUI
- From:
China Pharmacist
2017;20(6):1049-1051
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the utilization status of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in 11 hospitals of Zhejiang province from 2009 to 2015, and to analyze the use rationality.Methods: The doctor's advice in 40 days annually was collected in 11 hospitals of Zhejiang province from 2009 to 2015, and the drug consumption, frequency of utilization (DDDs), defined daily cost (DDC) and drug utilization index (DUI) were analyzed for the patients with lung cancer treated with EGFR-TKI.Results: Icotinib, erlotinib and gefitinib were the three prevalent EGFR-TKIs used in Zhejiang province, and icotinib started to be used in clinics in 2013.The overall cost of EGFR-TKIs increased year by year during 2009 and 2015, and the total amount of sales increased by 4.67 times in 2015 when compared with that in 2009.Generally, the DDDs value of erlotinib showed a decreasing trend, however, that of icotinib and gefitinib rose year by year during 2009 and 2015.Erlotinib had the highest DDC followed by gefitinib and icotinib.The mean value of DUI of the three targeted drugs was about 1.Conclusion: The utilization of EGFR-TKI is reasonable in 11 hospitals of Zhejiang province with increasing comsuption.
